LEI: 213800AV55PYXAS7SY24

5 October 2021

BIOPHARMA CREDIT PLC

(THE "COMPANY")

TRANSFER OF ORDINARY SHARES TO THE PREMIUM SEGMENT OF THE LONDON STOCK EXCHANGE AND INTRODUCTION OF STERLING QUOTE

Further to its announcement on 30 September 2021, BioPharma Credit plc (the "Company" or "BioPharma Credit") is pleased to announce the admission of all of its ordinary shares (the "Ordinary Shares") to listing on the Official List of the Financial Conduct Authority and to trading on the Premium Segment of London Stock Exchange plc's Main Market ("Admission"). The application for Admission was approved by shareholder vote at the general meeting held on 30 September 2021.

Admission is expected to become effective at 8:00 a.m. today. The Company's existing ticker, ISIN and SEDOL will remain unchanged.

The Company has applied to introduce an additional market quote for the Ordinary Shares on the London Stock Exchange denominated in GBP (the "GBP Quote"), in connection with which the Company will introduce a new ticker and SEDOL with effect from 8:00 a.m. on 5 October 2021, as set out below. The GBP Quote will appear alongside the Company's existing USD market quote (the "USD Quote") and there will be no changes to the legal form or nature of the Company's shares nor to the reporting currency of the Company's financial statements or the NAV (which will remain in USD). 

For Further Information

BioPharma Credit plc

Via Link Company Matters Limited

Company Secretary
+44 (0)1392 477 509

J.P. Morgan Cazenove                                       

William Simmonds / Harry Randall (Corporate Finance)

+44 (0)20 7742 4000

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000

[email protected]

About BioPharma Credit plc:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

Visit the BioPharma Credit website at http://bpcruk.com for more information.

Capitalised terms used but not defined in this announcement will have the same meaning as set out in the circular published by the Company on 10 September 2021 unless the context otherwise requires.